SELECT TOP (1000) [Source] ,[Taxon] ,[LowValue] ,[HighValue] ,[LowPCile] ,[HighPCile] FROM [DB_A5D9F7_Lassesen].[dbo].[JasonH]

Methanobrevibacter smithii Details: NCBI 2173, gram-negative or unknown [species]

| ATCC 35061| DSM 861| Methanobrevibacter smithii| Methanobrevibacter smithii Balch and Wolfe 1981| OCM 144| strain PS

  1. Digestive processes: Methanobrevibacter smithii is involved in the digestion of dietary carbohydrates in the human gut. It consumes hydrogen produced by other microorganisms during the fermentation of complex carbohydrates and uses it to produce methane. This process helps regulate the microbial ecosystem in the gut and influences the efficiency of energy extraction from the diet.

  2. Association with obesity: Some studies have suggested an association between the abundance of Methanobrevibacter smithii in the gut microbiota and obesity. Methane production by Methanobrevibacter smithii may influence energy metabolism and contribute to increased energy harvest from the diet. However, the exact mechanisms underlying this association and whether Methanobrevibacter smithii directly contributes to obesity or is simply a marker of dysbiosis are still under investigation.

  3. Inflammatory bowel disease (IBD): Methanobrevibacter smithii has been detected in the gut microbiota of individuals with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. However, its role in the pathogenesis of IBD is not fully understood. Some studies have suggested that methane production by Methanobrevibacter smithii may have anti-inflammatory effects in the gut, while others have proposed that it may exacerbate intestinal inflammation by altering microbial interactions.

  4. Hydrogen disposal: Methanobrevibacter smithii plays a role in hydrogen disposal in the gut by consuming hydrogen produced during microbial fermentation. In conditions where excess hydrogen accumulates in the gut, such as small intestinal bacterial overgrowth (SIBO), methane production by Methanobrevibacter smithii may help alleviate symptoms associated with hydrogen accumulation, such as bloating and abdominal discomfort.

  5. Potential therapeutic target: Given its abundance and potential role in gut health and disease, Methanobrevibacter smithii has been proposed as a potential therapeutic target for modulating the gut microbiota. Strategies aimed at selectively targeting Methanobrevibacter smithii, such as antimicrobial treatments or dietary interventions, are being investigated for their potential to modulate methane production and improve gastrointestinal health.

A lot more information is available when you are logged in and raise the display level

Other Sources for more information:

More Information
Statistics NCBI Data Punk End Products Produced

Lab Reporting

Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.

Desired Levels Suggestions for Methanobrevibacter smithii

These are values that are computed from lab specific samples (Patent Pending)
LabFrequencyUD-LowUD-HighKM LowKM HighLab LowLab HighMean MedianStandard DeviationBox Plot LowBox Plot High KM Percentile Low KM Percentile High
Other Labs 1.5 5 477000 0 181151 23124.7 8880 80625.7 0 25560 0 %ile 100 %ile
biomesight 22.42 0 20 10 9990 0 10419 1372.2 300 4615.6 0 1800 0 %ile 97.9 %ile
thryve 19.49 0 15 1 5393 0 16984 3418.6 696 6921.2 0 5204 0 %ile 92 %ile
ubiome 26.36 0 361 21 86128 0 41124 11576.9 5460 15075.3 0 25231 0 %ile 100 %ile

External Reference Ranges for Methanobrevibacter smithii

Methanobrevibacter smithii (NCBI 2173) per million
Source of Ranges Low Boundary High Boundary Low Boundary %age High Boundary %age
Thorne (20/80%ile) 0 190.4 0 0.019
Medivere 0 300 0 0.03
XenoGene 0 700 0 0.07
Statistic by Lab Source for Methanobrevibacter smithii
These desired values are reported from the lab reports
Lab Frequency Seen Average Standard Deviation Sample Count Lab Samples
BiomeSight 23.324 %   0.121 %  0.419 % 668.0 2864
bugspeak 100 %   0.007 %  % 1.0 1
CerbaLab 66.667 %   0.001 %  0 % 2.0 3
CosmosId 9.375 %   0.468 %  0.407 % 3.0 32
custom 42.373 %   1.541 %  0.476 % 25.0 59
es-xenogene 48.276 %   4.092 %  12.572 % 14.0 29
GanzimmunDiag 100 %   0.015 %  0 % 3.0 3
Microba 14.286 %   1.472 %  0.768 % 4.0 28
Microba1 100 %   2.67 %  % 1.0 1
SequentiaBiotech 5.556 %   0.664 %  0.551 % 2.0 36
Thorne 4.444 %   0.272 %  0.36 % 4.0 90
Thryve 19.595 %   0.308 %  0.663 % 271.0 1383
uBiome 26.389 %   1.169 %  1.513 % 209.0 792

Symptoms Associated with Methanobrevibacter smithii From Citizen Science Studies

Click on Impact for information if high or low levels are causing the impact

MagnitudeImpactSymptom

To see medical conditions associated you may be logged in

And display level must be raised above public.

I would like to know what can change the quality that I have

Data Contradictions β€” Limits of Certainity

To get the list of studies, you must be logged in and raise your display level.

πŸ§™? Search Hints:
General Substance Specific Substance Effect
Antibiotics, Antivirals etc ampicillin (antibiotic)s[CFS] 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Antibiotics, Antivirals etc bacitracin (antibiotic) 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Antibiotics, Antivirals etc gentamicin (antibiotic)s 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Antibiotics, Antivirals etc metronidazole (antibiotic)s[CFS] 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Antibiotics, Antivirals etc ofloxacin (antibiotic)s 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Antibiotics, Antivirals etc ornidazole (antibiotic)s 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Antibiotics, Antivirals etc rifampicin (antibiotic)s 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Antibiotics, Antivirals etc squalamine 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Antibiotics, Antivirals etc streptomycin (antibiotic)s 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Antibiotics, Antivirals etc tetracycline (antibiotic)s 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Diet Style high fodmap diet 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Drug or "Non-drug" amphotericin 2 Studies recorded. The consensus is Increases👶📓, Click for details.
Food (excluding seasonings) fruit/legume fibre 1 Studies recorded. The consensus is Increases📓, Click for details.
Food (excluding seasonings) lauric acid(fatty acid in coconut oil,in palm kernel oil,) 3 Studies recorded. The consensus is Decreases👶📓, Click for details.
Food (excluding seasonings) myristic acid(nutmeg butter, palm kernel oil, coconut oil, butterfat) 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Food (excluding seasonings) pomegranate 1 Studies recorded. The consensus is Decreases📓, Click for details.
Food (excluding seasonings) rice bran 1 Studies recorded. The consensus is Increases👶, Click for details.
Miscellaneous, food additives, and other odd items bile (acid/salts) 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Miscellaneous, food additives, and other odd items Bismuth Salts 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Miscellaneous, food additives, and other odd items bisphenol a (bpa) 1 Studies recorded. The consensus is Increases📓, Click for details.
Miscellaneous, food additives, and other odd items owning pet 1 Studies recorded. The consensus is Increases📓, Click for details.
Prescription - Other ethinylestradiol,(prescription) 1 Studies recorded. The consensus is Increases📓, Click for details.
Prescription - Other statins (prescription) 2 Studies recorded. The consensus is Decreases👶📓, Click for details.
Vitamins, Minerals and similar zinc 2 Studies recorded. The consensus is Increases👶📓, Click for details.

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)